Editor's Note The Department of Health and Human Services (HHS) announced on December 11 that it would purchase 100 million additional doses of Moderna’s COVID-19 vaccine. The vaccine, which was developed by Moderna with scientists from the National Institute of Allergy and Infectious Diseases (NIAID), is scheduled for a December…
Editor's Note After the Food and Drug Administration issued an Emergency Use Authorization for Pfizer/BioNTech’s COVID-19 vaccine on December 11, the company began shipping 2.9 million doses to 636 sites throughout the US. (https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19). On December 14, the first dose of the vaccine was administered at 9:23 am to an…
Editor's Note Gen Gustave Perna, who oversees logistics for Operation Warp Speed, announced December 8 that the government is prepared to distribute 2.9 million doses of Pfizer/BioNTech’s COVID-19 vaccine by the end of this week or immediately after the vaccine receives emergency use authorization (EUA) from the Food and Drug…
Editor's Note The Food and Drug Administration (FDA), on December 8, released documents that confirmed the safety and efficacy of Pfizer’s COVID-19 vaccine, the Associated Press reports. The vaccine was co-developed with BioNTech. FDA regulators posted their analysis online, as the UK began administering doses of the vaccine to its…
Editor's Note The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices, on December 1, recommended prioritizing healthcare workers and residents and workers in long-term-care facilities to be the first recipients of the upcoming COVID-19 vaccines. If CDC director Robert Redfield, MD, approves the recommendations, and the…
Editor's Note On November 30, Moderna applied for an emergency use authorization (EUA) from the Food & Drug Administration (FDA) for its COVID-19 vaccine. Moderna’s vaccine was developed in collaboration with researchers at the National Institute of Allergy and Infectious Diseases, where Anthony Fauci, MD, is the director. Moderna is…
Editor's Note The Food and Drug Administration (FDA) on November 17 issued an emergency use authorization for the first rapid COVID-19 self-test that a person can administer at home. The Lucira COVID-19 All-In-One Test Kit has to be prescribed by a healthcare provider, and the healthcare provider has to report…
Editor's Note Just a week after Pfizer revealed an interim analysis showing its COVID-19 vaccine to be more than 90% effective, the company on November 18 released its final efficacy analysis showing the vaccine is 95% effective, and that it protects older people who are most at risk of dying…
Most respondents to a July 2020 American Organization for Nursing Leadership survey said they felt prepared for a future surge of COVID-19. That future is now, with nearly 150,000 new cases being reported daily across the country and multiple hospitals at capacity. Survey respondents said their biggest challenges early in…
Editor's Note Moderna Inc (Cambridge, Massachusetts) on November 16 announced that its vaccine is 94.5% effective at preventing COVID-19. Their analysis of a 30,000-person trial (half received the vaccine and half received a placebo) finds that 90 of the 95 COVID-19 documented cases are in the placebo group. The Moderna announcement…